Company Profile
Hepion Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- HEPA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.06 USD (-14.16%)
Close
Last updated: August 6, 2026
—
Market cap
Why the stock is moving
As of Aug 6, 2026, HEPA closed down 14.2% at $0.0600. No new same-company headline was identified in the current news window.
Company overview
Business overview
Hepion Pharmaceuticals was a liver-disease biotechnology company focused on mitochondrial dysfunction and NASH-related biology before its restructuring and decline. Its legacy centered on a difficult metabolic-liver story.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ before restructuring, Hepion sat in specialty biotechnology.
Business Model Characteristics
The company depended on clinical validation, target biology, and the ability to translate liver-science into durable value.
Position Within the Biotechnology Landscape
Hepion belongs to the historical liver-biotech category rather than the current live public-company set.
Future catalysts
Hepion’s catalysts are HBV / liver-disease programs and any strategic update that clarifies the company’s direction. The market will want a clearer path before giving the story more credit.
Recent news
- 01
- 02
Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
Source: Hepion Pharmaceuticals
- 03
Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer
Source: Hepion Pharmaceuticals
- 04
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
Source: Hepion Pharmaceuticals
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Hepion Pharmaceuticals (HEPA)?
Hepion Pharmaceuticals (HEPA) most recently closed at 0.06 USD, a -14.16% move versus the previous session.
What does Hepion Pharmaceuticals do?
Hepion Pharmaceuticals was a liver-disease biotechnology company focused on mitochondrial dysfunction and NASH-related biology before its restructuring and decline. Its legacy centered on a difficult metabolic-liver story.
On which exchange is HEPA stock listed?
Hepion Pharmaceuticals (HEPA) is associated with NASDAQ, United States, Biopharma.
What is Hepion?
Hepion’s catalysts are HBV / liver-disease programs and any strategic update that clarifies the company’s direction.
Which conditions is Hepion Pharmaceuticals targeting with Hepion?
Hepion Pharmaceuticals is associated with metabolic disease based on its company overview and current catalyst commentary.
How does Hepion Pharmaceuticals describe recent progress with Hepion?
Hepion’s catalysts are HBV / liver-disease programs and any strategic update that clarifies the company’s direction.
What is Pharmaceuticals?
Hepion Pharmaceuticals was a liver-disease biotechnology company focused on mitochondrial dysfunction and NASH-related biology before its restructuring and decline.
What should investors watch for with Pharmaceuticals?
Hepion’s catalysts are HBV / liver-disease programs and any strategic update that clarifies the company’s direction. The market will want a clearer path before giving the story more credit.